Artivion, Inc. (AORT) Insider Trading Activity

NYSE$44.59
Market Cap
$2.11B
Sector
Healthcare
Industry
Medical—Devices
Rank in Sector
327 of 827
Rank in Industry
47 of 107

AORT Insider Trading Activity

AORT Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$53,141
1
2
Sells
$23,102,073
53
98

Related Transactions

SEMEDO ANTHONY B.director
1
$53,141
1
$74,027
$-20,887
Hoff Elizabeth Adirector
0
$0
1
$189,412
$-189,412
Berry Lance AExecutive VP, CFO
0
$0
2
$210,754
$-210,754
Horton AmyVP, Chief Accounting Officer
0
$0
7
$1.07M
$-1.07M
Davis John EChief Commercial Officer
0
$0
9
$2.17M
$-2.17M
Holloway Jean FSVP, General Counsel
0
$0
16
$4.74M
$-4.74M
Stanton Marshall S.SVP, Clinical & MD Affair
0
$0
10
$5.61M
$-5.61M
Mackin James PPresident & CEO
0
$0
7
$9.04M
$-9.04M

About Artivion, Inc.

Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.

Insider Activity of Artivion, Inc.

Over the last 12 months, insiders at Artivion, Inc. have bought $53,141 and sold $23.1M worth of Artivion, Inc. stock.

On average, over the past 5 years, insiders at Artivion, Inc. have bought $161,969 and sold $7.41M worth of stock each year.

Highest buying activity among insiders over the last 12 months: SEMEDO ANTHONY B. (director) — $53,141.

The last purchase of 2,100 shares for transaction amount of $53,141 was made by SEMEDO ANTHONY B. (director) on 2025‑03‑05.

List of Insider Buy and Sell Transactions, Artivion, Inc.

2025-12-03SaleMackin James PPresident & CEO
30,921
0.0651%
$45.46
$1.41M
-0.56%
2025-12-03SaleHolloway Jean FSVP, General Counsel
7,315
0.0154%
$45.30
$331,370
-0.56%
2025-12-02SaleMackin James PPresident & CEO
30,921
0.0657%
$45.56
$1.41M
-0.17%
2025-11-21SaleStanton Marshall S.SVP, Clinical & MD Affair
47,376
0.0998%
$45.04
$2.13M
+3.21%
2025-11-20SaleStanton Marshall S.SVP, Clinical & MD Affair
15,276
0.0323%
$44.18
$674,825
+2.19%
2025-11-18SaleHoff Elizabeth Adirector
4,200
0.0089%
$45.10
$189,412
+1.48%
2025-11-17SaleDavis John EChief Commercial Officer
6,394
0.0135%
$45.17
$288,817
-1.52%
2025-11-17SaleHolloway Jean FSVP, General Counsel
6,394
0.0135%
$45.17
$288,817
-1.52%
2025-11-17SaleHorton AmyVP, Chief Accounting Officer
6,000
0.0128%
$45.73
$274,380
-1.52%
2025-11-14SaleDavis John EChief Commercial Officer
6,393
0.0132%
$44.67
$285,575
+1.85%
2025-11-14SaleHolloway Jean FSVP, General Counsel
6,393
0.0133%
$45.00
$287,685
+1.85%
2025-11-13SaleMackin James PPresident & CEO
34,210
0.0727%
$45.86
$1.57M
-2.19%
2025-11-13SaleDavis John EChief Commercial Officer
6,563
0.014%
$45.86
$300,966
-2.19%
2025-11-13SaleHolloway Jean FSVP, General Counsel
5,761
0.0122%
$45.86
$264,188
-2.19%
2025-11-13SaleHorton AmyVP, Chief Accounting Officer
3,482
0.0074%
$45.86
$159,678
-2.19%
2025-11-13SaleStanton Marshall S.SVP, Clinical & MD Affair
4,993
0.0106%
$45.86
$228,969
-2.19%
2025-11-11SaleHolloway Jean FSVP, General Counsel
10,000
0.0218%
$46.18
$461,800
-0.17%
2025-11-10SaleMackin James PPresident & CEO
17,580
0.0371%
$44.62
$784,402
+0.38%
2025-11-10SaleDavis John EChief Commercial Officer
3,373
0.0071%
$44.62
$150,500
+0.38%
2025-11-10SaleHolloway Jean FSVP, General Counsel
2,960
0.0062%
$44.62
$132,072
+0.38%
Total: 284
*Gray background shows transactions not older than one year

Insider Historical Profitability

29.7%
Mackin James PPresident & CEO
800993
1.6909%
$35.72M423
+33.26%
Davis John EChief Commercial Officer
198842
0.4197%
$8.87M225
+28.47%
Holloway Jean FSVP, General Counsel
156093
0.3295%
$6.96M039
Berry Lance AExecutive VP, CFO
153431
0.3239%
$6.84M02
Horton AmyVP, Chief Accounting Officer
135380
0.2858%
$6.04M032
Stanton Marshall S.SVP, Clinical & MD Affair
44753
0.0945%
$2M017
SEMEDO ANTHONY B.director
39384
0.0831%
$1.76M22
+9.19%
Hoff Elizabeth Adirector
27189
0.0574%
$1.21M01
ANDERSON STEVEN GExecutive Chairman
1300676
2.7457%
$58M09
LEE DAVID ASHLEYExecutive VP, COO & CFO
347217
0.733%
$15.48M219
+25.04%
Capps Scott BVP, Clinical Research
148640
0.3138%
$6.63M05
McCall Ronald Ddirector
121768
0.257%
$5.43M022
FRONK DAVIDVP Reg. Affrs. and Qual Assur.
101528
0.2143%
$4.53M01
Burris Jeffrey WVice President & Gen. Counsel
93576
0.1975%
$4.17M05
Gale David CVP, Research & Development
77135
0.1628%
$3.44M02
SEERY GERALD BSr. VP, Sales and Marketing
71999
0.152%
$3.21M01
RONALD C ELKINSdirector
64843
0.1369%
$2.89M021
Benson Jamesdirector
54086
0.1142%
$2.41M05
Maney Rochelle L.VP, Quality
46569
0.0983%
$2.08M08
Maier Dennis BSVP, Operations
34724
0.0733%
$1.55M08
Anderson Bruce G.VP, US Sales &Global Marketing
34564
0.073%
$1.54M06
Getz Matthew AVP, Human Resources
34116
0.072%
$1.52M09
Bullock Jamesdirector
34023
0.0718%
$1.52M10
+47.76%
GREEN ANDREW MVP Regulatory
33503
0.0707%
$1.49M08
Tyrs FlorianVP, Global Operations
21558
0.0455%
$961,271.2203
*Gray background shows insiders who have made transactions during last year

AORT Institutional Investors: Active Positions

Increased Positions124+63.92%5M+11.48%
Decreased Positions79-40.72%4M-10.11%
New Positions48New2MNew
Sold Out Positions19Sold Out375,666Sold Out
Total Postitions239+23.2%42M+1.37%

AORT Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Blackrock, Inc.$282,276.0012.87%6.05M+48,727+0.81%2025-09-30
Vanguard Group Inc$141,336.006.45%3.03M+232,424+8.31%2025-09-30
Fmr Llc$139,428.006.36%2.99M+700,131+30.6%2025-09-30
Macquarie Group Ltd$115,896.005.29%2.48M-472,724-15.99%2025-09-30
Morgan Stanley$104,448.004.76%2.24M-80,166-3.46%2025-09-30
Perceptive Advisors Llc$94,253.004.3%2.02M-773,703-27.7%2025-09-30
State Street Corp$71,869.003.28%1.54M+25,417+1.68%2025-09-30
Wellington Management Group Llp$70,041.003.19%1.5M-212,336-12.39%2025-09-30
Juniper Investment Company, Llc$62,230.002.84%1.33M-760,257-36.31%2025-09-30
Fred Alger Management, Llc$61,463.002.8%1.32M-33,709-2.5%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.